Literature DB >> 20048110

The use of rhBMP-2 for the treatment of congenital pseudarthrosis of the tibia: a case series.

B Stephens Richards1, Matthew E Oetgen, Charles E Johnston.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20048110     DOI： 10.2106/JBJS.H.01667

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN： 0021-9355            Impact factor:   5.284


× No keyword cloud information.
  16 in total

1.  Bone morphogenetic protein-2 for the treatment of congenital pseudarthrosis of the tibia or persistent tibial nonunion in children and adolescents: A retrospective study with a minimum 2-year follow-up.

Authors:  Tim N Hissnauer; Norbert Stiel; Kornelia Babin; Martin Rupprecht; Michael Hoffmann; Johannes M Rueger; Ralf Stuecker; Alexander S Spiro
Journal:  J Mater Sci Mater Med       Date:  2017-02-17       Impact factor: 3.896

2.  Bone morphogenetic protein and orthopaedic surgery: can we legitimate its off-label use?

Authors:  Aurélien Courvoisier; Frederic Sailhan; Olivier Laffenêtre; Laurent Obert
Journal:  Int Orthop       Date:  2014-09-30       Impact factor: 3.075

3.  Preliminary experience with the combined use of recombinant bone morphogenetic protein and bisphosphonates in the treatment of congenital pseudarthrosis of the tibia.

Authors:  Oliver Birke; Aaron Schindeler; Manoj Ramachandran; Chris T Cowell; Craig F Munns; Michael Bellemore; David G Little
Journal:  J Child Orthop       Date:  2010-10-21       Impact factor: 1.548

4.  Successful treatment of congenital pseudarthrosis of the tibia: still a challenge.

Authors:  K Bobotas; S N Lallos; V S Nikolaou; D S Kοrres; N E Efstathopoulos
Journal:  Eur J Orthop Surg Traumatol       Date:  2012-09-02

5.  Masquelet's procedure and bone morphogenetic protein in congenital pseudarthrosis of the tibia in children: a case series and meta-analysis.

Authors:  Bruno Dohin; Remi Kohler
Journal:  J Child Orthop       Date:  2012-07-21       Impact factor: 1.548

6.  Evaluation of complications associated with off-label use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in pediatric orthopaedics.

Authors:  Norbert Stiel; Tim N Hissnauer; Martin Rupprecht; Kornelia Babin; Carsten W Schlickewei; Johannes M Rueger; Ralf Stuecker; Alexander S Spiro
Journal:  J Mater Sci Mater Med       Date:  2016-10-27       Impact factor: 3.896

Review 7.  Anterolateral Tibial Bowing and Congenital Pseudoarthrosis of the Tibia: Current Concept Review and Future Directions.

Authors:  Matthew J Siebert; Christopher A Makarewich
Journal:  Curr Rev Musculoskelet Med       Date:  2022-07-16

8.  Congenital pseudarthrosis of the tibia: the results of an evolving protocol of management.

Authors:  N Nicolaou; A Ghassemi; R A Hill
Journal:  J Child Orthop       Date:  2013-06-12       Impact factor: 1.548

9.  Effectiveness of recombinant human bone morphogenetic protein-7 in the management of congenital pseudoarthrosis of the tibia: a randomised controlled trial.

Authors:  Sakti Prasad Das; Shankar Ganesh; Sudhakar Pradhan; Deepak Singh; Ram Narayan Mohanty
Journal:  Int Orthop       Date:  2014-05-15       Impact factor: 3.075

10.  Ilizarov bone transport as a treatment of congenital pseudarthrosis of the tibia: a long-term follow-up study.

Authors:  Jan Vanderstappen; Johan Lammens; Pieter Berger; Armand Laumen
Journal:  J Child Orthop       Date:  2015-08-13       Impact factor: 1.548
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.